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  In the 1920s, when the genetic theory 
of cancer was taking root, German 
biochemist Otto Warburg (winner of 
the 1931 Nobel prize in physiology or 
medicine) proposed that abnormal 
energy metabolism caused cancer. Cells 
can generate energy either through 
oxidative respiration in mitochondria 
or through glycolysis in the cytoplasm. 
Warburg showed that tumors have an 
acidic extracellular environment, and 
he argued that a switch from oxidative 
respiration to glycolysis—which 
produces lactic acid—sets the cell down 
the path to cancer. 
    Though most cancer researchers 
think this glycolytic shift is a by-
product rather than a cause of cancer, 
Warburg’s work stimulated interest in 
the possibility that there was some kind 
of link between pH and cancer. And 
now, a new study by Rui Zhao, Denis 
Alexander, and colleagues shows why 
manipulating the intracellular pH of 
tumor cells may indeed turn out to be a 
promising anticancer strategy. 
    Cells typically respond to genetic 
injury by triggering a carefully 
regulated program called apoptosis 
that kills cells with aberrant DNA so 
they don’t persist and spawn malignant 
progeny. In healthy cells, “pro-survival” 
proteins like Bcl-xL keep “pro-
apoptotic” proteins like Bim in check. 
Recent work by other groups showed 
that DNA damage rapidly “deamidates” 
asparagine (Asn) amino acid residues 
in Bcl-xL —that is, removes their amide 
functional groups—converting Asn 
into aspartic acid (Asp). Now regarded 
as one of the most common post-
translational protein modiﬁ  cations, Asn 
deamidation can substantially alter a 
protein’s function.
    The ﬁ  nding that DNA damage can 
induce Asn deamidation suggests that 
it is a regulated event, challenging the 
established view that deamidation rates 
are predetermined only by a protein’s 
structural properties. These studies 
also suggested that damage-induced 
deamidation causes apoptosis, based 
on observations that deamidated 
Bcl-xL failed to inhibit pro-apoptotic 
Bim proteins in cells that died. But 
this link between Bcl-xL deamidation 
and apoptosis was called into question 
when additional experiments showed 
that deamidated Bcl-xL proteins could 
block pro-apoptotic proteins, and thus 
apoptosis, after all. 
    Against this background, Zhao et al. 
investigated the biochemical path from 
DNA damage to Bcl-xL deamidation 
along with its physiological 
consequences. Based on their own 
previous work—which showed that an 
oncogenic enzyme inhibited Bcl-xL 
deamidation, promoted Bcl-xL–Bim 
binding, and allowed DNA-damaged 
developing T cells (called thymocytes) 
to survive in a mouse model of T cell 
lymphoma—the researchers concluded 
that Bcl-xL deamidation is a “critical 
switch” in transforming T cells. And 
they suspected that the conﬂ  icting 
ﬁ  ndings about deamidated Bcl-xL’s 
role in apoptosis reﬂ  ected the fact 
that when Asn amino acid residues are 
deamidated, it’s mainly an isomer of 
Asp that results (iso-Aspartate or iso-
Asp), not Asp itself.
    Zhao et al. ﬁ  rst determined that 
DNA-damage–triggered Bcl-xL 
deamidation is the cause, rather than 
the result, of apoptosis. Working in 
mouse thymocytes, they showed that 
inhibiting apoptosis in DNA-damaged 
cells did not inhibit Bcl-xL deamidation, 
which occurred 3 to 6 hours after 
DNA injury and proceeded along with 
increased apoptosis. 
    The model that Bcl-xL deamidation 
triggers apoptosis assumes that Bcl-xL 
promotes survival by sequestering 
the pro-apoptotic proteins. Since 
this activity represents the critical 
molecular link between DNA damage 
and apoptosis, the authors used a 
series of cellular and biochemical 
approaches to test this assumption. 
Working with oncogene-expressing but 
precancerous mouse thymocytes that 
resist deamidation, the authors found 
both Bim and another pro-apoptotic 
protein, Puma, bound to nonmodiﬁ  ed 
Bcl-xL. Normal cells, however, could not 
sequester the pro-apoptotic proteins 
after DNA damage, indicating that 
deamidated Bcl-xL can’t bind them. 
    They tested this conclusion by 
exposing puriﬁ  ed recombinant Bcl-xL 
to alkaline conditions that induced 
partial Bcl-xL deamidation and 
produced three Bcl-xL species, each 
with different deamidation proﬁ  les. 
Only one of these forms—in which 
Asn converts to iso-Asp—prevents the 
sequestration of the pro-apoptotic 
proteins. This isomerized form disrupts 
Bcl-xL’s structure enough to prevent 
it from binding Bim or Puma. It’s well 
known that iso-Asp has important 
structural, and thus functional, 
implications for a broad range of 
proteins, because it puts a ‘kink’ into 
the amino acid backbone of proteins 
that Asp doesn’t.       
    Having observed that elevated 
pH speeds up Asn deamidation 
rates, the authors investigated the 
possibility that alkalinization induces 
deamidation in the thymocytes. While 
pH levels did not change in the 
precancerous cells, it rose in response 
to DNA damage in nonmutant 
cells—an increase associated with 
signiﬁ  cant Bcl-xL deamidation. In fact, 
artiﬁ  cially increasing the alkalinity 
of the DNA-damaged precancerous 
thymocytes—normally resistant to 
deamidation—triggered deamidation. 
Even in thymocytes without DNA 
damage, alkalinization led to 
considerable Bcl-xL deamidation along 
with increased apoptosis. Importantly, 
precancerous thymocytes artiﬁ  cially 
engineered to express Bcl-xL species 
that can sequester Bim survived, despite 
enforced alkalinization.
    But what regulates the rise in pH 
inside the cell? DNA damage triggers 
increased production of a plasma 
membrane protein known as the 
Na/H exchanger (NHE-1), or antiport 
(because it exchanges extracellular 
sodium ions with cytoplasmic hydrogen 
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ions), which allows for a higher efﬂ  ux 
of hydrogen ions, thereby raising the 
intracellular pH. 
    Altogether, these results chart the 
molecular path to Bcl-xL deamidation: 
DNA damage triggers a 2- to 3-fold 
increase in the production of NHE-
1, allowing an efﬂ  ux of hydrogen 
ions, which raises intracellular pH. 
Alkalinization, in turn, deamidates two 
Bcl-xL Asn residues into iso-Asp, which 
alters the pro-survival protein’s shape, 
preventing it from binding to and 
sequestering pro-apoptotic proteins, 
leading to apoptosis. 
    To determine whether the novel 
signaling pathway they had elucidated 
in mouse cells might have relevance 
to human cancer cells, the authors 
also studied cells from patients with 
chronic lymphocytic leukemia (CLL). 
They found that when the intracellular 
pH was raised artiﬁ  cially, both Bcl-xL 
deamidation and apoptosis resulted. 
    Though Warburg’s metabolic theory 
of cancer never gained traction, his 
work highlighted a possible connection 
between pH and cancer—and now, 
70 years later, that link is receiving 
experimental support. Many different 
tumor types appear to use Bcl-xL to 
bypass apoptosis, rendering some 
cancer cells resistant to therapy. This 
suggests that inducing alkalinization—
possibly by enhancing NHE-1 
expression or increasing its activity—to 
promote Bcl-xL deamidation and 
thus apoptosis may prove an effective 
strategy to treat a range of cancers. 
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